Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Implementation of and Satisfaction with an Outpatient Oral Anticancer Therapy Program

Emily R. Mackler, PharmD, BCOP, Oncology Clinical Pharmacist, Michigan Oncology Quality Consortium at the University of Michigan Comprehensive Cancer Center, and Adjunct Clinical Associate Professor at the University of Michigan College of Pharmacy, Ann Arbor, discusses the clinical significance of her study, “Implementation of and Satisfaction with an Outpatient Oral Anticancer Therapy Program.”
Related Items
Comparing the Efficacy and Safety of Reference Drug Filgrastim and Biosimilar Filgrastim-sndz in Pediatric Patients Used for Post–Hematopoietic Stem-Cell Transplant Engraftment or Chemotherapy-Induced Febrile Neutropenia Prophylaxis
JHOP - February 2023 Vol 13, No 1 published on February 27, 2023 in Original Article
Dosing of 3 Targeted Agents in Novel Drug Combinations Used at the Precision Medicine Clinic of the University of California San Diego
JHOP - February 2023 Vol 13, No 1 published on February 27, 2023 in Original Article
Economic Burden of Cardiovascular Events in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the First Year After Initiating Treatment with a Novel Agent
JHOP - February 2023 Vol 13, No 1 published on February 27, 2023 in Original Article
Incidence of Hypothyroidism in Patients with Cancer Receiving Immune Checkpoint Inhibitors
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in Original Article
Assessment of the Elimination of Test Doses for Paclitaxel and Carboplatin in Patients with Cancer
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in Original Article
Outcomes and Adverse Events Linked to Off-Label Treatment of Solid Tumors with PARP Inhibitors
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in Original Article
Impact of Pharmacist Telephone Follow-Up on Chemotherapy-Induced Nausea and Vomiting
JHOP - October 2022 Vol 12, No 5 published on October 21, 2022 in Original Article
Evaluating Institutional Safety Standards Related to Continuing Oral Antineoplastic Medication Use During Hospitalization
JHOP - October 2022 Vol 12, No 5 published on October 21, 2022 in Original Article
Time to First Palbociclib Prescription Dispense at Mayo Clinic: Comparing a Health-System Specialty Pharmacy with External Specialty Pharmacies
JHOP - October 2022 Vol 12, No 5 published on October 20, 2022 in Original Article
Comparing the Impact of Abiraterone and Enzalutamide Sequencing on Progression-Free Survival in Veterans with Metastatic Castration-Resistant Prostate Cancer
JHOP - August 2022 Vol 12, No 4 published on August 19, 2022 in Original Article, Prostate Cancer, Genitourinary Cancers, Targeted Therapies
Copyright © Amplity Health. All rights reserved.